ILIAS

Pipeline

table

Inflammatory
Diseases

Exosomes loaded with anti-inflammatory proteins
targeting the core inflammation signaling pathway
within the cell can be applied to treat both acute
and chronic inflammatory diseases.

Oncology

Exosomes loaded with intracellular antibodies are in
development to inhibit the growth and metastasis
of malignant tumors. They target the oncogenic
proteins of cancer cells or tumor-associated immune cells

CNS Diseases

Engineered exosomes with targeting moieties enhance targeted
delivery across the BBB, and they open new possibilities
to target previously undruggable CNS diseases.

Pipeline Expandability

The broad applicability of EXPLOR® and Exo-Target® platforms make it possible to target previously
inaccessible areas and unlock new potential across a range of therapeutic areas.

Intracellular Antibodies (Intrabodies)
Novel treatment modality enabling inhibition of traditionally undruggable intracellular targets,
such as those that function through large protein-protein interactions
Intracellular Signaling Proteins & Transcription Factors
Capability to directly target multiple downstream pathways of traditional extracellular routes
for novel therapeutic effect
Organelle-specific Proteins
Organelle-specific trafficking moieties can be attached to exosome cargo to achieve effective
trafficking to the mitochondria and nucleus, offering a new modality for targeted enzyme
replacement and other applications
Gene-editing Protein
ILIAS is actively working towards the ability to load EXPLOR® exosomes with gene-editing proteins
such as CRISPR/Cas9 to achieve targeted gene editing in vivo